The Conversation (0)
Actavis plc (NYSE:ACT) announced that it’s entered an agreement to divest the US rights to Doryx® brand acne treatment and related assets to Mayne Pharma Group Ltd. (ASX:MYX).
Actavis plc (NYSE:ACT) announced that it’s entered an agreement to divest the US rights to Doryx® brand acne treatment and related assets to Mayne Pharma Group Ltd. (ASX:MYX).
As quoted in the press release:
The transaction is expected to close prior to the end of February. Under the terms of the agreement,Actavis will continue to package, distribute and actively promote the product for a transition period until May 2 following the close of the transaction.
Click here to read the full Actavis plc (NYSE:ACT) press release.